Research progress on the role of miRNA in drug resistance of pleural mesothelioma
- VernacularTitle:miRNA在胸膜间皮瘤耐药中的作用研究进展
- Author:
Xinmeng WANG
1
,
2
;
Jinsong LI
1
,
2
;
Yaru LIN
1
,
2
;
Ximin TANG
1
,
2
;
Yuanqian PU
1
,
2
;
Jiaji ZI
1
,
2
;
Wei XIONG
1
,
2
Author Information
1. School of Basic Medical Sciences，Dali University，Yunnan Dali 671000，China
2. Key Laboratory of Clinical Biochemistry of Yunnan Province，Yunnan Dali 671000，China
- Publication Type:Journal Article
- Keywords:
miRNA;
pleural mesothelioma;
targeted therapy;
drug resistance
- From:
China Pharmacy
2024;35(22):2832-2836
- CountryChina
- Language:Chinese
-
Abstract:
Pleural mesothelioma （PM） is a rare malignant tumor originating from the pleura. Most patients are already in the advanced stage at the time of diagnosis， resulting in a low overall survival rate. MicroRNA （miRNA）， as key regulators of tumor epigenetic modification， have an intertwined interactive network with PM drug resistance. The mechanisms of drug resistance in PM to chemotherapeutic drugs include increasing drug efflux， reducing drug intake， enhancing DNA repair， and altering drug targets. The mechanisms of resistance to targeted therapy drugs include activating alternative signaling pathways， establishing a favorable tumor microenvironment， and triggering epithelial-mesenchymal transition. MiRNA plays a key part in the aforementioned resistance mechanisms， with some miRNAs promoting the drug sensitivity of cancer cells， while others contribute to increased drug resistance. In light of these key regulatory functions， targeting the dysregulated expression of endogenous miRNAs in the process of resistance formation using miRNA antagonists or miRNA mimics may be an effective therapeutic strategy to reverse drug resistance in PM.
